DiaMedica TherapeuticsDMAC
DMAC
About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Employees: 28
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
533% more call options, than puts
Call options by funds: $57K | Put options by funds: $9K
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
27% more funds holding
Funds holding: 45 [Q4 2024] → 57 (+12) [Q1 2025]
1.8% more ownership
Funds ownership: 15.74% [Q4 2024] → 17.53% (+1.8%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
22% less capital invested
Capital invested by funds: $36.5M [Q4 2024] → $28.5M (-$8.06M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
175%
upside
Avg. target
$10
175%
upside
High target
$10
175%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield | 175%upside $10 | Buy Reiterated | 29 May 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investa.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one meetings with investors to discuss the co.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Ton.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit:.
Neutral
Seeking Alpha
1 month ago
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2025 financial results. Preeclampsia Phase 2 C.
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wai.
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details:.
Neutral
Seeking Alpha
3 months ago
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call.
Neutral
Business Wire
3 months ago
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2024 financial results. “We made significant progr.
Charts implemented using Lightweight Charts™